Journal Title：Advanced Drug Delivery Reviews

The aim of the Journal is to provide a forum for the critical analysis of advanced drug and gene delivery systems and their applications in human and veterinary medicine. The Journal has a broad scope, covering the key issues for effective drug and gene delivery, from administration to site-specific delivery.

In general, the Journal publishes review articles in a Theme Issue format. Each Theme Issue provides a comprehensive and critical examination of current and emerging research on the design and development of advanced drug and gene delivery systems and their application to experimental and clinical therapeutics. The goal is to illustrate the pivotal role of a multidisciplinary approach to modern drug delivery, encompassing the application of sound biological and physicochemical principles to the engineering of drug delivery systems to meet the therapeutic need at hand. Importantly the Editorial Team of ADDR asks that the authors effectively window the extensive volume of literature, pick the important contributions and explain their importance, produce a forward looking identification of the challenges facing the field and produce a Conclusions section with expert recommendations to address the issues.

Articles review the current status of a specific topic, giving equal emphasis to the identification of major conceptual and technological challenges to successful drug and gene delivery, to an evaluation of triumphs as well as shortcomings in current conceptual and technical approaches, and to a discussion of their possible solution.

本期刊旨在為對先進藥物和基因遞送系統及其在人類和獸醫學中的應用進行批判性分析提供一個論壇。本期刊涵蓋范圍廣泛，涵蓋有效藥物和基因遞送的關鍵問題，從給藥到位點遞送。

一般來說，本期刊以專題期刊的形式發表評論文章。每個專題期刊都對先進藥物和基因遞送系統的設計和開發及其在實驗和臨床治療中的應用的當前和新興研究進行全面和批判性的審查。其目標是說明多學科方法在現代藥物遞送中的關鍵作用，包括將合理的生物學和物理化學原理應用于藥物遞送系統的工程設計以滿足當前的治療需求。重要的是，ADDR 的編輯團隊要求作者有效地瀏覽大量文獻，挑選出重要的貢獻并解釋其重要性，對該領域面臨的挑戰進行前瞻性的識別，并撰寫結論部分，其中包含專家建議以解決問題。

文章回顧了特定主題的當前狀態，同樣強調識別成功藥物和基因遞送的主要概念和技術挑戰，評估當前概念和技術方法的成功和不足，并討論其可能的解決方案。

Advanced Drug Delivery Reviews創刊于1987年，由Elsevier出版商出版，收稿方向涵蓋藥學 - 醫學全領域，在行業領域中學術影響力很大，屬于TOP期刊，國際一流期刊，關注度和專業度非常高，所以對原創文章要求創新性很高，過審難度很高，如果您有志于TOP期刊，建議關注此刊。平均審稿速度 一般,3-8周 約15.1周，影響因子指數15.2，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。